Neogap strengthens its board with two new members
Neogap Therapeutics AB, developing individualised immunotherapy for cancer treatment, strengthens the board with two new members. Anna Kälvemark and Steve Glavas both have experience in transforming start-ups into successful companies and contribute with cutting-edge expertise in regulatory activities and commercialisation of life science companies.
At Neogap Therapeutics' annual general meeting on May 20, Anna Kälvemark and Steve Glavas were elected new board members.
"We would like to extend a warm welcome to Anna Kälvemark and Steve Glavas to Neogap's board. They are an ideal complement to Neogap's board at a stage when we are about to enter the clinical phase," says Johan Lund, Chairman of the Board of Directors at Neogap.
"Anna Kälvemark and Steve Glavas add significant value with their experience of successful company building and leadership of life science companies. Anna Kälvemark also strengthens Neogap with her excellence in regulatory activities and Steve Glavas with his broad experience in commercialising companies in the life science industry," says Johan Lund.
Anna Kälvemark is the founder and CEO of Complyit, a leading consulting company in life science, which she has developed from a start-up to a profitable business with over 100 consultants. She has extensive experience in corporate governance and Regulatory Compliance within pharmaceuticals, biotechnology, and medical technology.
Steve Glavas has solid experience in business development, commercialisation, and biotechnological applications for, among other things, DNA sequencing in oncology and a vast international network of contacts. He was previously Vice President & General Manager at Celsee, Inc. and Sales Executive at 10X Genomics.
For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94
Email: samuel.svensson@neogap.se
About Neogap Therapeutics
NEOGAP Therapeutics is a Swedish biotechnology company that develops individualised immunotherapy for the treatment of cancer using the patient's own cells. The therapy is based on the company's two technologies: PIOR®, a software using DNA sequencing data from the patient and machine learning to select tumour-specific mutations; and EpiTCer®, a method for proliferating the T cells that recognize the selected tumour-specific target structures. NEOGAP is located at the Center for Molecular Medicine, Karolinska Institutet in Stockholm. For more information, visit the company's website neogap.se.
Tags:
